Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-06-28
2011-06-28
Kolker, Daniel E (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S007240
Reexamination Certificate
active
07968293
ABSTRACT:
The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
REFERENCES:
patent: 2004/0014109 (2004-01-01), Pericak-Vance et al.
patent: 2004/0053251 (2004-03-01), Pericak-Vance et al.
patent: 2006/0003327 (2006-01-01), Achiron et al.
patent: 2006/0183117 (2006-08-01), Pericak-Vance et al.
patent: 2006/0211060 (2006-09-01), Haley et al.
patent: 2008/0045582 (2008-02-01), Zineh et al.
patent: 2010/0009377 (2010-01-01), Wohlgemuth et al.
patent: 2010/0112568 (2010-05-01), Achiron et al.
patent: WO 02/059604 (2002-08-01), None
patent: WO 02/059604 (2002-08-01), None
patent: WO 2005/027733 (2005-03-01), None
patent: WO 2005/027733 (2005-03-01), None
patent: WO 2005/067391 (2005-07-01), None
patent: WO 2005/067391 (2005-07-01), None
patent: WO 2006/077126 (2006-07-01), None
patent: WO 2006/077126 (2006-07-01), None
Sapan CV et al. Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics. Vox Sanguinis, Apr. 2007; 92:197-205.
Andersson, U. et al., “Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes,”Immunological Reviews, 1994, vol. 139, pp. 21-42.
Basta, M. et al., “High Doses of Intravenous Ig Inhibit In Vitro Uptake of C4 Fragments Onto Sensitized Erythrocytes,”Blood, Jan. 15, 1991, vol. 77, No. 2, pp. 376-380.
Bayary, J. et al., “Intravenous immunoglobulin in autoimmune disorders: an insight into the immunregulatory mechanisms,”International Immunopharmacology, 2006, vol. 6, pp. 528-534.
Bayry, J. et al., “Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases,”Neurol. Sci., 2003, vol. 24, pp. S217-S221.
Bayry, J. et al., “Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory disease,”Transfusion Clinique et Biologique, 2003, vol. 10, pp. 165-169.
Calabresi, P.A. et al., “Diagnosis and Management of Multiple Sclerosis,”American Family Physician, Nov. 15, 2004, vol. 70, No. 10, pp. 1935-1944.
Dalakas, M.C., “Intravenous Immune Globulin Therapy for Neurologic Diseases,”Annals of Internal Medicine, May 1, 1997, vol. 126, No. 9, pp. 721-730.
Dudesek, A. et al., “Intravenouse immunoglobuline as therapeutic option in the treatment of multiple sclerosis,”J. Neurol., 2006, vol. 253 (Suppl. 5), pp. V/50-V/58.
Hellings, N. et al., “Insights into the Immunopathogenesis of Multiple Sclerosis,”Immunologic Research, 2002, vol. 1, pp. 27-51.
Huang, D. et al., “Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice,”The FASEB Journal, May 2005, vol. 19, pp. 761-722.
Kazatchkine, M.D. et al., “Mechanism of action of intravenous immunoglobulin (IVIG),”Multiple Sclerosis, 2000, vol. 2 (Suppl. 2), pp. S24-526. or vol. 33, pp. 24-26.
Kim, Y.S. et al., “Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease,”Experimental and Molecular Medicine, Aug. 2006, vol. 38, No. 4, pp. 333-347.
Lewanska, M. et al., “No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment,”European Journal of Neurology, 2002, vol. 9, pp. 565-572.
Samuelsson, A. et al., “Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor,”Science, Jan. 19, 2001, vol. 291, pp. 484-486.
Sorensen, P.S. et al., “Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis,”European Journal of Neurology, 2002, vol. 9, pp. 557-563.
Sørensen, P.S., “Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials,”Neurol. Sci., 2003, vol. 24, pp. S227-S230.
Sorenson, P.S. et al., “Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis,”Neurology, May 1998, vol. 50, pp. 1273-1281.
Sospedra, M. et al., “Immunology of Multiple Sclerosis,”Annu. Rev. Immunol., 2005, vol. 23, pp. 683-747.
Stangel, M. et al., “Hochdosierte intravenöse Immunglobuline in der Behandlung der Multiples Sklerose,”Nervenarzt, 2005, vol. 76, pp. 1267-1272.
Strasser-Fuchs, S. et al., “The Austrian Immunoglobulin in MS (AIMS) study: final analysis,”Multiple Sclerosis, 2000, vol. 6 (Suppl. 2), pp. S9-S13.
Trebst, C. et al., “Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis,”Current Pharmaceutical Design, 2006, vol. 12, No. 2, pp. 241-249.
Wilms, H. et al., “Inflammation in Parkinson's Diseases and Other Neurodegenerative Disease: Cause and Therapeutic Implications,”Current Pharmaceutical Design, 2007, vol. 13, No. 18, pp. 1925-1928.
Yamamoto, M. et al., “Overexpression of Monocyte Chemotactic Protein-1/CCLS2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition,”American Journal of Pathology, May 2005, vol. 166, No. 5, pp. 1475-1485.
Partial International Search Report mailed on Feb. 17, 2009, for International Application No. PCT/EP2008/006608, filed on Aug. 11, 2008, 3 pages.
Ehrlich Hartmut
Elovaara Irina
Reipert Birgit
Schwarz Hans-Peter
Ballard Kimberly A.
Baxter Healthcare S.A.
Baxter International Inc.
Kolker Daniel E
Morgan, Lewis & Bockius, LLC
LandOfFree
IVIG modulation of chemokines for treatment of multiple... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IVIG modulation of chemokines for treatment of multiple..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IVIG modulation of chemokines for treatment of multiple... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730988